References:
1. Starzl TE, Fung JJ. Themes of liver transplantation.HEPATOLOGY (2010) 51 : 1869-1884.
2.
Watt
KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of
causes and risk factors for mortality post-liver transplant: results of
the NIDDK long-term follow-up study. AM J TRANSPLANT (2010)10 : 1420-1427.
3. Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in
liver transplant recipients. Liver Transpl (2011) 17
Suppl 3 : S1-S9.
4.
Kwong
AJ, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA et al .
OPTN/SRTR 2019 Annual Data Report: Liver. AM J TRANSPLANT (2021)21 Suppl 2 : 208-315.
5.
Rana
A, Ackah RL, Webb GJ, Halazun KJ, Vierling JM, Liu H et al . No
Gains in Long-term Survival After Liver Transplantation Over the Past
Three Decades. ANN SURG (2019) 269 : 20-27.
6. Aberg F, Gissler M, Karlsen TH, Ericzon BG, Foss A, Rasmussen Aet al . Differences in long-term survival among liver transplant
recipients and the general population: a population-based Nordic study.HEPATOLOGY (2015) 61 : 668-677.
7. Mukherjee S, Mukherjee U. A Comprehensive Review of Immunosuppression
Used for Liver Transplantation. Journal of Transplantation (2009)2009 : 1-20.
8.
Tasdogan
BE, Ma M, Simsek C, Saberi B, Gurakar A. Update on Immunosuppression in
Liver Transplantation. Euroasian J Hepatogastroenterol (2019)9 : 96-101.
9.
McAlister
VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin
versus tacrolimus as primary immunosuppressant after liver
transplantation: a meta-analysis. AM J TRANSPLANT (2006)6 : 1578-1585.
10. Pflugrad H, Schrader AK, Tryc AB, Ding X, Lanfermann H, Jackel Eet al . Longterm calcineurin inhibitor therapy and brain function
in patients after liver transplantation. Liver Transpl (2018)24 : 56-66.
11. Rodriguez-Peralvarez M, Guerrero-Misas M, Thorburn D, Davidson BR,
Tsochatzis E, Gurusamy KS. Maintenance immunosuppression for adults
undergoing liver transplantation: a network meta-analysis.Cochrane Database Syst Rev (2017) 3 : D11639.
12.
Beresford
T. Neuropsychiatric complications of liver and other solid organ
transplantation. LIVER TRANSPLANT (2001) 7 : S36-S45.
13. Pruitt A. Neurological complications after solid organ
transplantation. J NEUROL SCI (2015) 357 : e483.
14. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee Wet al . Clinical Pharmacogenetics Implementation Consortium (CPIC)
Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. CLIN
PHARMACOL THER (2015) 98 : 19-24.
15.
Fukudo
M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T et al .
Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in
pediatric living-donor liver transplant recipients. CLIN PHARMACOL
THER (2006) 80 : 331-345.
16. Staatz CE, Tett SE. Clinical Pharmacokinetics and Pharmacodynamics
of Tacrolimus in Solid Organ Transplantation. Adis International: Cham
2004:623-653.
17. de
Wildt SN, van Schaik RHN, Soldin OP, Soldin SJ, Brojeni PY, van der
Heiden IP et al . The interactions of age, genetics, and disease
severity on tacrolimus dosing requirements after pediatric kidney and
liver transplantation. EUR J CLIN PHARMACOL (2011) 67 :
1231-1241.
18.
Calvo
PL, Serpe L, Brunati A, Nonnato A, Bongioanni D, Olio DD et al .
DonorCYP3A5 genotype influences tacrolimus disposition on the first day
after paediatric liver transplantation. BRIT J CLIN PHARMACO(2017) 83 : 1252-1262.
19. BuendÃa JA, Halac E, Bosaleh A, Garcia De Davila MT, Imvertasa O,
Bramuglia G. Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus
Pharmacokinetics in Pediatric Liver Transplantation.PHARMACEUTICS (2020) 12 : 898.
20. Th
Rn M, Lundgren S, Herlenius G, Ericzon BR, L F L, Rane A. Gene
expression of cytochromes P 450 in liver transplants over time.EUR J CLIN PHARMACOL (2004) 60 .
21. Ince I, Knibbe CAJ, Danhof M, de Wildt SN. Developmental Changes in
the Expression and Function of Cytochrome P450 3A Isoforms: Evidence
from In Vitro and In Vivo Investigations. CLIN PHARMACOKINET(2013) 52 : 333-345.
Table 1. Comparison between CsA
and TAC